Pharma & Healthcare
Global Oncolytic Adenovirus Market Research Report 2025
- Apr 16, 25
- ID: 201485
- Pages: 105
- Figures: 106
- Views: 2
The global market for Oncolytic Adenovirus was valued at US$ 1500 million in the year 2024 and is projected to reach a revised size of US$ 4666 million by 2031, growing at a CAGR of 17.6% during the forecast period.
Oncolytic adenovirus is a type of adenovirus that has been genetically engineered to selectively replicate within tumor cells and cause cell lysis, while also stimulating the body's immune system to fight against tumors. This type of virus originates from adenovirus that exists in nature and usually has low pathogenicity to the human body. After modification, it has acquired the ability to specifically target and kill tumor cells. According to the degree of genetic modification, it can be divided into two categories: conditional replication type and armed type. The former involves deleting or mutating genes related to normal cell replication in the viral genome, allowing it to only replicate effectively in tumor cells, while the latter carries additional therapeutic genes (such as cytokines, tumor suppressor genes, etc.) while retaining its oncolytic ability, further enhancing its anti-tumor effect.
The global oncolytic adenovirus market has shown a rapid growth trend in recent years. The global burden of cancer continues to increase, creating a huge unmet medical need. Traditional cancer treatment methods, such as chemotherapy and radiotherapy, have significant limitations, which have driven the development of innovative therapies such as oncolytic viruses. The advancement of biotechnology has reduced the research and production costs of oncolytic adenovirus, and the favor of the capital market has provided sufficient financial support for the industry. North America currently dominates the global market, followed closely by Europe. Although the Asia Pacific region (especially China) started relatively late, it has enormous growth potential. At present, oncolytic adenovirus is mainly used for the treatment of solid tumors, and its indications are showing a diversified trend. The market competition is fierce, and multinational companies such as Merck, Roche, and Amgen rely on their strong research and development capabilities, financial support, and extensive market channels to continuously launch new products and expand market share through mergers and acquisitions, cooperation, and other means. Meanwhile, emerging biotechnology companies such as Viralytics are gradually emerging, focusing on the research and innovation of oncolytic adenovirus. Through technological innovation and clinical trials, they develop products with differentiated advantages. From a technological perspective, the competition in the field of oncolytic adenovirus mainly focuses on vector optimization, arming strategies, and combination therapies. Vector optimization technology is currently the core direction of oncolytic adenovirus research and development. Armed oncolytic adenovirus represents one of the most promising technological routes, and combination therapy strategies have become the mainstream paradigm for clinical development of oncolytic adenovirus. In addition, innovative drug delivery routes are a key link in improving the efficacy of oncolytic adenovirus, and optimizing production processes is a necessary path for oncolytic adenovirus to move from the laboratory to the market. In the future, oncolytic adenovirus technology will develop towards intelligence and multifunctionality. The next generation of oncolytic adenovirus may have environmental responsiveness, autonomously regulating replication intensity based on tumor microenvironment signals, or designed as a "modular platform" that allows for flexible loading of therapeutic gene combinations according to different tumor types. In addition, the cross-border integration of oncolytic adenovirus with emerging technologies such as nanomaterials and electric field therapy will also create new therapeutic possibilities.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncolytic Adenovirus, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Adenovirus.
The Oncolytic Adenovirus market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncolytic Adenovirus market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Adenovirus manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Merck
Roche
Transgene
Agenus
Oncorus
Viralytics
Amgen
Targovax
Sorrento Therapeutics
Shanghai Pharma Sunway Biotech
Jiangsu Hengrui Pharmaceuticals
Fosun Pharma
BeiGene
Junshi Biosciences
Chengdu Kanghua Biological Products
3SBio
Changchun High & New Technology Industries
Segment by Type
Conditional Replication Adenovirus
Armed Oncolytic Adenovirus
Segment by Application
Head And Neck Cancer
Liver Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Glioblastoma
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncolytic Adenovirus manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncolytic Adenovirus in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Oncolytic adenovirus is a type of adenovirus that has been genetically engineered to selectively replicate within tumor cells and cause cell lysis, while also stimulating the body's immune system to fight against tumors. This type of virus originates from adenovirus that exists in nature and usually has low pathogenicity to the human body. After modification, it has acquired the ability to specifically target and kill tumor cells. According to the degree of genetic modification, it can be divided into two categories: conditional replication type and armed type. The former involves deleting or mutating genes related to normal cell replication in the viral genome, allowing it to only replicate effectively in tumor cells, while the latter carries additional therapeutic genes (such as cytokines, tumor suppressor genes, etc.) while retaining its oncolytic ability, further enhancing its anti-tumor effect.
The global oncolytic adenovirus market has shown a rapid growth trend in recent years. The global burden of cancer continues to increase, creating a huge unmet medical need. Traditional cancer treatment methods, such as chemotherapy and radiotherapy, have significant limitations, which have driven the development of innovative therapies such as oncolytic viruses. The advancement of biotechnology has reduced the research and production costs of oncolytic adenovirus, and the favor of the capital market has provided sufficient financial support for the industry. North America currently dominates the global market, followed closely by Europe. Although the Asia Pacific region (especially China) started relatively late, it has enormous growth potential. At present, oncolytic adenovirus is mainly used for the treatment of solid tumors, and its indications are showing a diversified trend. The market competition is fierce, and multinational companies such as Merck, Roche, and Amgen rely on their strong research and development capabilities, financial support, and extensive market channels to continuously launch new products and expand market share through mergers and acquisitions, cooperation, and other means. Meanwhile, emerging biotechnology companies such as Viralytics are gradually emerging, focusing on the research and innovation of oncolytic adenovirus. Through technological innovation and clinical trials, they develop products with differentiated advantages. From a technological perspective, the competition in the field of oncolytic adenovirus mainly focuses on vector optimization, arming strategies, and combination therapies. Vector optimization technology is currently the core direction of oncolytic adenovirus research and development. Armed oncolytic adenovirus represents one of the most promising technological routes, and combination therapy strategies have become the mainstream paradigm for clinical development of oncolytic adenovirus. In addition, innovative drug delivery routes are a key link in improving the efficacy of oncolytic adenovirus, and optimizing production processes is a necessary path for oncolytic adenovirus to move from the laboratory to the market. In the future, oncolytic adenovirus technology will develop towards intelligence and multifunctionality. The next generation of oncolytic adenovirus may have environmental responsiveness, autonomously regulating replication intensity based on tumor microenvironment signals, or designed as a "modular platform" that allows for flexible loading of therapeutic gene combinations according to different tumor types. In addition, the cross-border integration of oncolytic adenovirus with emerging technologies such as nanomaterials and electric field therapy will also create new therapeutic possibilities.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncolytic Adenovirus, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Adenovirus.
The Oncolytic Adenovirus market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncolytic Adenovirus market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Adenovirus manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Merck
Roche
Transgene
Agenus
Oncorus
Viralytics
Amgen
Targovax
Sorrento Therapeutics
Shanghai Pharma Sunway Biotech
Jiangsu Hengrui Pharmaceuticals
Fosun Pharma
BeiGene
Junshi Biosciences
Chengdu Kanghua Biological Products
3SBio
Changchun High & New Technology Industries
Segment by Type
Conditional Replication Adenovirus
Armed Oncolytic Adenovirus
Segment by Application
Head And Neck Cancer
Liver Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Glioblastoma
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncolytic Adenovirus manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncolytic Adenovirus in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Oncolytic Adenovirus Market Overview
1.1 Product Definition
1.2 Oncolytic Adenovirus by Type
1.2.1 Global Oncolytic Adenovirus Market Value Comparison by Type (2024 VS 2031)
1.2.2 Conditional Replication Adenovirus
1.2.3 Armed Oncolytic Adenovirus
1.3 Oncolytic Adenovirus by Application
1.3.1 Global Oncolytic Adenovirus Market Value by Application (2024 VS 2031)
1.3.2 Head And Neck Cancer
1.3.3 Liver Cancer
1.3.4 Colorectal Cancer
1.3.5 Prostate Cancer
1.3.6 Ovarian Cancer
1.3.7 Non-Small Cell Lung Cancer
1.3.8 Glioblastoma
1.3.9 Others
1.4 Global Oncolytic Adenovirus Market Size Estimates and Forecasts
1.4.1 Global Oncolytic Adenovirus Revenue 2020-2031
1.4.2 Global Oncolytic Adenovirus Sales 2020-2031
1.4.3 Global Oncolytic Adenovirus Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Oncolytic Adenovirus Market Competition by Manufacturers
2.1 Global Oncolytic Adenovirus Sales Market Share by Manufacturers (2020-2025)
2.2 Global Oncolytic Adenovirus Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Oncolytic Adenovirus Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Oncolytic Adenovirus, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oncolytic Adenovirus, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oncolytic Adenovirus, Product Type & Application
2.7 Global Key Manufacturers of Oncolytic Adenovirus, Date of Enter into This Industry
2.8 Global Oncolytic Adenovirus Market Competitive Situation and Trends
2.8.1 Global Oncolytic Adenovirus Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oncolytic Adenovirus Players Market Share by Revenue
2.8.3 Global Oncolytic Adenovirus Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oncolytic Adenovirus Market Scenario by Region
3.1 Global Oncolytic Adenovirus Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Oncolytic Adenovirus Sales by Region: 2020-2031
3.2.1 Global Oncolytic Adenovirus Sales by Region: 2020-2025
3.2.2 Global Oncolytic Adenovirus Sales by Region: 2026-2031
3.3 Global Oncolytic Adenovirus Revenue by Region: 2020-2031
3.3.1 Global Oncolytic Adenovirus Revenue by Region: 2020-2025
3.3.2 Global Oncolytic Adenovirus Revenue by Region: 2026-2031
3.4 North America Oncolytic Adenovirus Market Facts & Figures by Country
3.4.1 North America Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Oncolytic Adenovirus Sales by Country (2020-2031)
3.4.3 North America Oncolytic Adenovirus Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oncolytic Adenovirus Market Facts & Figures by Country
3.5.1 Europe Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Oncolytic Adenovirus Sales by Country (2020-2031)
3.5.3 Europe Oncolytic Adenovirus Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncolytic Adenovirus Market Facts & Figures by Region
3.6.1 Asia Pacific Oncolytic Adenovirus Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Oncolytic Adenovirus Sales by Region (2020-2031)
3.6.3 Asia Pacific Oncolytic Adenovirus Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oncolytic Adenovirus Market Facts & Figures by Country
3.7.1 Latin America Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Oncolytic Adenovirus Sales by Country (2020-2031)
3.7.3 Latin America Oncolytic Adenovirus Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oncolytic Adenovirus Market Facts & Figures by Country
3.8.1 Middle East and Africa Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Oncolytic Adenovirus Sales by Country (2020-2031)
3.8.3 Middle East and Africa Oncolytic Adenovirus Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oncolytic Adenovirus Sales by Type (2020-2031)
4.1.1 Global Oncolytic Adenovirus Sales by Type (2020-2025)
4.1.2 Global Oncolytic Adenovirus Sales by Type (2026-2031)
4.1.3 Global Oncolytic Adenovirus Sales Market Share by Type (2020-2031)
4.2 Global Oncolytic Adenovirus Revenue by Type (2020-2031)
4.2.1 Global Oncolytic Adenovirus Revenue by Type (2020-2025)
4.2.2 Global Oncolytic Adenovirus Revenue by Type (2026-2031)
4.2.3 Global Oncolytic Adenovirus Revenue Market Share by Type (2020-2031)
4.3 Global Oncolytic Adenovirus Price by Type (2020-2031)
5 Segment by Application
5.1 Global Oncolytic Adenovirus Sales by Application (2020-2031)
5.1.1 Global Oncolytic Adenovirus Sales by Application (2020-2025)
5.1.2 Global Oncolytic Adenovirus Sales by Application (2026-2031)
5.1.3 Global Oncolytic Adenovirus Sales Market Share by Application (2020-2031)
5.2 Global Oncolytic Adenovirus Revenue by Application (2020-2031)
5.2.1 Global Oncolytic Adenovirus Revenue by Application (2020-2025)
5.2.2 Global Oncolytic Adenovirus Revenue by Application (2026-2031)
5.2.3 Global Oncolytic Adenovirus Revenue Market Share by Application (2020-2031)
5.3 Global Oncolytic Adenovirus Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Oncolytic Adenovirus Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Oncolytic Adenovirus Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Transgene
6.3.1 Transgene Company Information
6.3.2 Transgene Description and Business Overview
6.3.3 Transgene Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Transgene Oncolytic Adenovirus Product Portfolio
6.3.5 Transgene Recent Developments/Updates
6.4 Agenus
6.4.1 Agenus Company Information
6.4.2 Agenus Description and Business Overview
6.4.3 Agenus Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Agenus Oncolytic Adenovirus Product Portfolio
6.4.5 Agenus Recent Developments/Updates
6.5 Oncorus
6.5.1 Oncorus Company Information
6.5.2 Oncorus Description and Business Overview
6.5.3 Oncorus Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Oncorus Oncolytic Adenovirus Product Portfolio
6.5.5 Oncorus Recent Developments/Updates
6.6 Viralytics
6.6.1 Viralytics Company Information
6.6.2 Viralytics Description and Business Overview
6.6.3 Viralytics Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Viralytics Oncolytic Adenovirus Product Portfolio
6.6.5 Viralytics Recent Developments/Updates
6.7 Amgen
6.7.1 Amgen Company Information
6.7.2 Amgen Description and Business Overview
6.7.3 Amgen Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Amgen Oncolytic Adenovirus Product Portfolio
6.7.5 Amgen Recent Developments/Updates
6.8 Targovax
6.8.1 Targovax Company Information
6.8.2 Targovax Description and Business Overview
6.8.3 Targovax Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Targovax Oncolytic Adenovirus Product Portfolio
6.8.5 Targovax Recent Developments/Updates
6.9 Sorrento Therapeutics
6.9.1 Sorrento Therapeutics Company Information
6.9.2 Sorrento Therapeutics Description and Business Overview
6.9.3 Sorrento Therapeutics Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sorrento Therapeutics Oncolytic Adenovirus Product Portfolio
6.9.5 Sorrento Therapeutics Recent Developments/Updates
6.10 Shanghai Pharma Sunway Biotech
6.10.1 Shanghai Pharma Sunway Biotech Company Information
6.10.2 Shanghai Pharma Sunway Biotech Description and Business Overview
6.10.3 Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Product Portfolio
6.10.5 Shanghai Pharma Sunway Biotech Recent Developments/Updates
6.11 Jiangsu Hengrui Pharmaceuticals
6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.11.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.11.3 Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Product Portfolio
6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.12 Fosun Pharma
6.12.1 Fosun Pharma Company Information
6.12.2 Fosun Pharma Description and Business Overview
6.12.3 Fosun Pharma Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Fosun Pharma Oncolytic Adenovirus Product Portfolio
6.12.5 Fosun Pharma Recent Developments/Updates
6.13 BeiGene
6.13.1 BeiGene Company Information
6.13.2 BeiGene Description and Business Overview
6.13.3 BeiGene Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.13.4 BeiGene Oncolytic Adenovirus Product Portfolio
6.13.5 BeiGene Recent Developments/Updates
6.14 Junshi Biosciences
6.14.1 Junshi Biosciences Company Information
6.14.2 Junshi Biosciences Description and Business Overview
6.14.3 Junshi Biosciences Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Junshi Biosciences Oncolytic Adenovirus Product Portfolio
6.14.5 Junshi Biosciences Recent Developments/Updates
6.15 Chengdu Kanghua Biological Products
6.15.1 Chengdu Kanghua Biological Products Company Information
6.15.2 Chengdu Kanghua Biological Products Description and Business Overview
6.15.3 Chengdu Kanghua Biological Products Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Chengdu Kanghua Biological Products Oncolytic Adenovirus Product Portfolio
6.15.5 Chengdu Kanghua Biological Products Recent Developments/Updates
6.16 3SBio
6.16.1 3SBio Company Information
6.16.2 3SBio Description and Business Overview
6.16.3 3SBio Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.16.4 3SBio Oncolytic Adenovirus Product Portfolio
6.16.5 3SBio Recent Developments/Updates
6.17 Changchun High & New Technology Industries
6.17.1 Changchun High & New Technology Industries Company Information
6.17.2 Changchun High & New Technology Industries Description and Business Overview
6.17.3 Changchun High & New Technology Industries Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Changchun High & New Technology Industries Oncolytic Adenovirus Product Portfolio
6.17.5 Changchun High & New Technology Industries Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncolytic Adenovirus Industry Chain Analysis
7.2 Oncolytic Adenovirus Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncolytic Adenovirus Production Mode & Process Analysis
7.4 Oncolytic Adenovirus Sales and Marketing
7.4.1 Oncolytic Adenovirus Sales Channels
7.4.2 Oncolytic Adenovirus Distributors
7.5 Oncolytic Adenovirus Customer Analysis
8 Oncolytic Adenovirus Market Dynamics
8.1 Oncolytic Adenovirus Industry Trends
8.2 Oncolytic Adenovirus Market Drivers
8.3 Oncolytic Adenovirus Market Challenges
8.4 Oncolytic Adenovirus Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Oncolytic Adenovirus by Type
1.2.1 Global Oncolytic Adenovirus Market Value Comparison by Type (2024 VS 2031)
1.2.2 Conditional Replication Adenovirus
1.2.3 Armed Oncolytic Adenovirus
1.3 Oncolytic Adenovirus by Application
1.3.1 Global Oncolytic Adenovirus Market Value by Application (2024 VS 2031)
1.3.2 Head And Neck Cancer
1.3.3 Liver Cancer
1.3.4 Colorectal Cancer
1.3.5 Prostate Cancer
1.3.6 Ovarian Cancer
1.3.7 Non-Small Cell Lung Cancer
1.3.8 Glioblastoma
1.3.9 Others
1.4 Global Oncolytic Adenovirus Market Size Estimates and Forecasts
1.4.1 Global Oncolytic Adenovirus Revenue 2020-2031
1.4.2 Global Oncolytic Adenovirus Sales 2020-2031
1.4.3 Global Oncolytic Adenovirus Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Oncolytic Adenovirus Market Competition by Manufacturers
2.1 Global Oncolytic Adenovirus Sales Market Share by Manufacturers (2020-2025)
2.2 Global Oncolytic Adenovirus Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Oncolytic Adenovirus Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Oncolytic Adenovirus, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oncolytic Adenovirus, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oncolytic Adenovirus, Product Type & Application
2.7 Global Key Manufacturers of Oncolytic Adenovirus, Date of Enter into This Industry
2.8 Global Oncolytic Adenovirus Market Competitive Situation and Trends
2.8.1 Global Oncolytic Adenovirus Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oncolytic Adenovirus Players Market Share by Revenue
2.8.3 Global Oncolytic Adenovirus Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oncolytic Adenovirus Market Scenario by Region
3.1 Global Oncolytic Adenovirus Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Oncolytic Adenovirus Sales by Region: 2020-2031
3.2.1 Global Oncolytic Adenovirus Sales by Region: 2020-2025
3.2.2 Global Oncolytic Adenovirus Sales by Region: 2026-2031
3.3 Global Oncolytic Adenovirus Revenue by Region: 2020-2031
3.3.1 Global Oncolytic Adenovirus Revenue by Region: 2020-2025
3.3.2 Global Oncolytic Adenovirus Revenue by Region: 2026-2031
3.4 North America Oncolytic Adenovirus Market Facts & Figures by Country
3.4.1 North America Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Oncolytic Adenovirus Sales by Country (2020-2031)
3.4.3 North America Oncolytic Adenovirus Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oncolytic Adenovirus Market Facts & Figures by Country
3.5.1 Europe Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Oncolytic Adenovirus Sales by Country (2020-2031)
3.5.3 Europe Oncolytic Adenovirus Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncolytic Adenovirus Market Facts & Figures by Region
3.6.1 Asia Pacific Oncolytic Adenovirus Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Oncolytic Adenovirus Sales by Region (2020-2031)
3.6.3 Asia Pacific Oncolytic Adenovirus Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oncolytic Adenovirus Market Facts & Figures by Country
3.7.1 Latin America Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Oncolytic Adenovirus Sales by Country (2020-2031)
3.7.3 Latin America Oncolytic Adenovirus Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oncolytic Adenovirus Market Facts & Figures by Country
3.8.1 Middle East and Africa Oncolytic Adenovirus Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Oncolytic Adenovirus Sales by Country (2020-2031)
3.8.3 Middle East and Africa Oncolytic Adenovirus Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oncolytic Adenovirus Sales by Type (2020-2031)
4.1.1 Global Oncolytic Adenovirus Sales by Type (2020-2025)
4.1.2 Global Oncolytic Adenovirus Sales by Type (2026-2031)
4.1.3 Global Oncolytic Adenovirus Sales Market Share by Type (2020-2031)
4.2 Global Oncolytic Adenovirus Revenue by Type (2020-2031)
4.2.1 Global Oncolytic Adenovirus Revenue by Type (2020-2025)
4.2.2 Global Oncolytic Adenovirus Revenue by Type (2026-2031)
4.2.3 Global Oncolytic Adenovirus Revenue Market Share by Type (2020-2031)
4.3 Global Oncolytic Adenovirus Price by Type (2020-2031)
5 Segment by Application
5.1 Global Oncolytic Adenovirus Sales by Application (2020-2031)
5.1.1 Global Oncolytic Adenovirus Sales by Application (2020-2025)
5.1.2 Global Oncolytic Adenovirus Sales by Application (2026-2031)
5.1.3 Global Oncolytic Adenovirus Sales Market Share by Application (2020-2031)
5.2 Global Oncolytic Adenovirus Revenue by Application (2020-2031)
5.2.1 Global Oncolytic Adenovirus Revenue by Application (2020-2025)
5.2.2 Global Oncolytic Adenovirus Revenue by Application (2026-2031)
5.2.3 Global Oncolytic Adenovirus Revenue Market Share by Application (2020-2031)
5.3 Global Oncolytic Adenovirus Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Oncolytic Adenovirus Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Oncolytic Adenovirus Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Transgene
6.3.1 Transgene Company Information
6.3.2 Transgene Description and Business Overview
6.3.3 Transgene Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Transgene Oncolytic Adenovirus Product Portfolio
6.3.5 Transgene Recent Developments/Updates
6.4 Agenus
6.4.1 Agenus Company Information
6.4.2 Agenus Description and Business Overview
6.4.3 Agenus Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Agenus Oncolytic Adenovirus Product Portfolio
6.4.5 Agenus Recent Developments/Updates
6.5 Oncorus
6.5.1 Oncorus Company Information
6.5.2 Oncorus Description and Business Overview
6.5.3 Oncorus Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Oncorus Oncolytic Adenovirus Product Portfolio
6.5.5 Oncorus Recent Developments/Updates
6.6 Viralytics
6.6.1 Viralytics Company Information
6.6.2 Viralytics Description and Business Overview
6.6.3 Viralytics Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Viralytics Oncolytic Adenovirus Product Portfolio
6.6.5 Viralytics Recent Developments/Updates
6.7 Amgen
6.7.1 Amgen Company Information
6.7.2 Amgen Description and Business Overview
6.7.3 Amgen Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Amgen Oncolytic Adenovirus Product Portfolio
6.7.5 Amgen Recent Developments/Updates
6.8 Targovax
6.8.1 Targovax Company Information
6.8.2 Targovax Description and Business Overview
6.8.3 Targovax Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Targovax Oncolytic Adenovirus Product Portfolio
6.8.5 Targovax Recent Developments/Updates
6.9 Sorrento Therapeutics
6.9.1 Sorrento Therapeutics Company Information
6.9.2 Sorrento Therapeutics Description and Business Overview
6.9.3 Sorrento Therapeutics Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sorrento Therapeutics Oncolytic Adenovirus Product Portfolio
6.9.5 Sorrento Therapeutics Recent Developments/Updates
6.10 Shanghai Pharma Sunway Biotech
6.10.1 Shanghai Pharma Sunway Biotech Company Information
6.10.2 Shanghai Pharma Sunway Biotech Description and Business Overview
6.10.3 Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Product Portfolio
6.10.5 Shanghai Pharma Sunway Biotech Recent Developments/Updates
6.11 Jiangsu Hengrui Pharmaceuticals
6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.11.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.11.3 Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Product Portfolio
6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.12 Fosun Pharma
6.12.1 Fosun Pharma Company Information
6.12.2 Fosun Pharma Description and Business Overview
6.12.3 Fosun Pharma Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Fosun Pharma Oncolytic Adenovirus Product Portfolio
6.12.5 Fosun Pharma Recent Developments/Updates
6.13 BeiGene
6.13.1 BeiGene Company Information
6.13.2 BeiGene Description and Business Overview
6.13.3 BeiGene Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.13.4 BeiGene Oncolytic Adenovirus Product Portfolio
6.13.5 BeiGene Recent Developments/Updates
6.14 Junshi Biosciences
6.14.1 Junshi Biosciences Company Information
6.14.2 Junshi Biosciences Description and Business Overview
6.14.3 Junshi Biosciences Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Junshi Biosciences Oncolytic Adenovirus Product Portfolio
6.14.5 Junshi Biosciences Recent Developments/Updates
6.15 Chengdu Kanghua Biological Products
6.15.1 Chengdu Kanghua Biological Products Company Information
6.15.2 Chengdu Kanghua Biological Products Description and Business Overview
6.15.3 Chengdu Kanghua Biological Products Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Chengdu Kanghua Biological Products Oncolytic Adenovirus Product Portfolio
6.15.5 Chengdu Kanghua Biological Products Recent Developments/Updates
6.16 3SBio
6.16.1 3SBio Company Information
6.16.2 3SBio Description and Business Overview
6.16.3 3SBio Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.16.4 3SBio Oncolytic Adenovirus Product Portfolio
6.16.5 3SBio Recent Developments/Updates
6.17 Changchun High & New Technology Industries
6.17.1 Changchun High & New Technology Industries Company Information
6.17.2 Changchun High & New Technology Industries Description and Business Overview
6.17.3 Changchun High & New Technology Industries Oncolytic Adenovirus Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Changchun High & New Technology Industries Oncolytic Adenovirus Product Portfolio
6.17.5 Changchun High & New Technology Industries Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncolytic Adenovirus Industry Chain Analysis
7.2 Oncolytic Adenovirus Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncolytic Adenovirus Production Mode & Process Analysis
7.4 Oncolytic Adenovirus Sales and Marketing
7.4.1 Oncolytic Adenovirus Sales Channels
7.4.2 Oncolytic Adenovirus Distributors
7.5 Oncolytic Adenovirus Customer Analysis
8 Oncolytic Adenovirus Market Dynamics
8.1 Oncolytic Adenovirus Industry Trends
8.2 Oncolytic Adenovirus Market Drivers
8.3 Oncolytic Adenovirus Market Challenges
8.4 Oncolytic Adenovirus Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Oncolytic Adenovirus Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Oncolytic Adenovirus Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Oncolytic Adenovirus Market Competitive Situation by Manufacturers in 2024
Table 4. Global Oncolytic Adenovirus Sales (Units) of Key Manufacturers (2020-2025)
Table 5. Global Oncolytic Adenovirus Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Oncolytic Adenovirus Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Oncolytic Adenovirus Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Oncolytic Adenovirus Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Oncolytic Adenovirus, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oncolytic Adenovirus, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oncolytic Adenovirus, Product Type & Application
Table 12. Global Key Manufacturers of Oncolytic Adenovirus, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oncolytic Adenovirus by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Adenovirus as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oncolytic Adenovirus Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Oncolytic Adenovirus Sales by Region (2020-2025) & (Units)
Table 18. Global Oncolytic Adenovirus Sales Market Share by Region (2020-2025)
Table 19. Global Oncolytic Adenovirus Sales by Region (2026-2031) & (Units)
Table 20. Global Oncolytic Adenovirus Sales Market Share by Region (2026-2031)
Table 21. Global Oncolytic Adenovirus Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Oncolytic Adenovirus Revenue Market Share by Region (2020-2025)
Table 23. Global Oncolytic Adenovirus Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Oncolytic Adenovirus Revenue Market Share by Region (2026-2031)
Table 25. North America Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 27. North America Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 28. North America Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 32. Europe Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 33. Europe Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Oncolytic Adenovirus Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Oncolytic Adenovirus Sales by Region (2020-2025) & (Units)
Table 37. Asia Pacific Oncolytic Adenovirus Sales by Region (2026-2031) & (Units)
Table 38. Asia Pacific Oncolytic Adenovirus Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Oncolytic Adenovirus Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 42. Latin America Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 43. Latin America Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 47. Middle East and Africa Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 48. Middle East and Africa Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Oncolytic Adenovirus Sales (Units) by Type (2020-2025)
Table 51. Global Oncolytic Adenovirus Sales (Units) by Type (2026-2031)
Table 52. Global Oncolytic Adenovirus Sales Market Share by Type (2020-2025)
Table 53. Global Oncolytic Adenovirus Sales Market Share by Type (2026-2031)
Table 54. Global Oncolytic Adenovirus Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Oncolytic Adenovirus Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Oncolytic Adenovirus Revenue Market Share by Type (2020-2025)
Table 57. Global Oncolytic Adenovirus Revenue Market Share by Type (2026-2031)
Table 58. Global Oncolytic Adenovirus Price (US$/Unit) by Type (2020-2025)
Table 59. Global Oncolytic Adenovirus Price (US$/Unit) by Type (2026-2031)
Table 60. Global Oncolytic Adenovirus Sales (Units) by Application (2020-2025)
Table 61. Global Oncolytic Adenovirus Sales (Units) by Application (2026-2031)
Table 62. Global Oncolytic Adenovirus Sales Market Share by Application (2020-2025)
Table 63. Global Oncolytic Adenovirus Sales Market Share by Application (2026-2031)
Table 64. Global Oncolytic Adenovirus Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Oncolytic Adenovirus Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Oncolytic Adenovirus Revenue Market Share by Application (2020-2025)
Table 67. Global Oncolytic Adenovirus Revenue Market Share by Application (2026-2031)
Table 68. Global Oncolytic Adenovirus Price (US$/Unit) by Application (2020-2025)
Table 69. Global Oncolytic Adenovirus Price (US$/Unit) by Application (2026-2031)
Table 70. Merck Company Information
Table 71. Merck Description and Business Overview
Table 72. Merck Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Merck Oncolytic Adenovirus Product
Table 74. Merck Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Roche Oncolytic Adenovirus Product
Table 79. Roche Recent Developments/Updates
Table 80. Transgene Company Information
Table 81. Transgene Description and Business Overview
Table 82. Transgene Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Transgene Oncolytic Adenovirus Product
Table 84. Transgene Recent Developments/Updates
Table 85. Agenus Company Information
Table 86. Agenus Description and Business Overview
Table 87. Agenus Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Agenus Oncolytic Adenovirus Product
Table 89. Agenus Recent Developments/Updates
Table 90. Oncorus Company Information
Table 91. Oncorus Description and Business Overview
Table 92. Oncorus Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Oncorus Oncolytic Adenovirus Product
Table 94. Oncorus Recent Developments/Updates
Table 95. Viralytics Company Information
Table 96. Viralytics Description and Business Overview
Table 97. Viralytics Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Viralytics Oncolytic Adenovirus Product
Table 99. Viralytics Recent Developments/Updates
Table 100. Amgen Company Information
Table 101. Amgen Description and Business Overview
Table 102. Amgen Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Amgen Oncolytic Adenovirus Product
Table 104. Amgen Recent Developments/Updates
Table 105. Targovax Company Information
Table 106. Targovax Description and Business Overview
Table 107. Targovax Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Targovax Oncolytic Adenovirus Product
Table 109. Targovax Recent Developments/Updates
Table 110. Sorrento Therapeutics Company Information
Table 111. Sorrento Therapeutics Description and Business Overview
Table 112. Sorrento Therapeutics Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sorrento Therapeutics Oncolytic Adenovirus Product
Table 114. Sorrento Therapeutics Recent Developments/Updates
Table 115. Shanghai Pharma Sunway Biotech Company Information
Table 116. Shanghai Pharma Sunway Biotech Description and Business Overview
Table 117. Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Product
Table 119. Shanghai Pharma Sunway Biotech Recent Developments/Updates
Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 122. Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Product
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 125. Fosun Pharma Company Information
Table 126. Fosun Pharma Description and Business Overview
Table 127. Fosun Pharma Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Fosun Pharma Oncolytic Adenovirus Product
Table 129. Fosun Pharma Recent Developments/Updates
Table 130. BeiGene Company Information
Table 131. BeiGene Description and Business Overview
Table 132. BeiGene Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. BeiGene Oncolytic Adenovirus Product
Table 134. BeiGene Recent Developments/Updates
Table 135. Junshi Biosciences Company Information
Table 136. Junshi Biosciences Description and Business Overview
Table 137. Junshi Biosciences Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Junshi Biosciences Oncolytic Adenovirus Product
Table 139. Junshi Biosciences Recent Developments/Updates
Table 140. Chengdu Kanghua Biological Products Company Information
Table 141. Chengdu Kanghua Biological Products Description and Business Overview
Table 142. Chengdu Kanghua Biological Products Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Chengdu Kanghua Biological Products Oncolytic Adenovirus Product
Table 144. Chengdu Kanghua Biological Products Recent Developments/Updates
Table 145. 3SBio Company Information
Table 146. 3SBio Description and Business Overview
Table 147. 3SBio Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. 3SBio Oncolytic Adenovirus Product
Table 149. 3SBio Recent Developments/Updates
Table 150. Changchun High & New Technology Industries Company Information
Table 151. Changchun High & New Technology Industries Description and Business Overview
Table 152. Changchun High & New Technology Industries Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Changchun High & New Technology Industries Oncolytic Adenovirus Product
Table 154. Changchun High & New Technology Industries Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Oncolytic Adenovirus Distributors List
Table 158. Oncolytic Adenovirus Customers List
Table 159. Oncolytic Adenovirus Market Trends
Table 160. Oncolytic Adenovirus Market Drivers
Table 161. Oncolytic Adenovirus Market Challenges
Table 162. Oncolytic Adenovirus Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oncolytic Adenovirus
Figure 2. Global Oncolytic Adenovirus Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oncolytic Adenovirus Market Share by Type: 2024 & 2031
Figure 4. Conditional Replication Adenovirus Product Picture
Figure 5. Armed Oncolytic Adenovirus Product Picture
Figure 6. Global Oncolytic Adenovirus Market Value by Application (2020-2031) & (US$ Million)
Figure 7. Global Oncolytic Adenovirus Market Share by Application: 2024 & 2031
Figure 8. Head And Neck Cancer
Figure 9. Liver Cancer
Figure 10. Colorectal Cancer
Figure 11. Prostate Cancer
Figure 12. Ovarian Cancer
Figure 13. Non-Small Cell Lung Cancer
Figure 14. Glioblastoma
Figure 15. Others
Figure 16. Global Oncolytic Adenovirus Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Oncolytic Adenovirus Market Size (2020-2031) & (US$ Million)
Figure 18. Global Oncolytic Adenovirus Sales (2020-2031) & (Units)
Figure 19. Global Oncolytic Adenovirus Average Price (US$/Unit) & (2020-2031)
Figure 20. Oncolytic Adenovirus Report Years Considered
Figure 21. Oncolytic Adenovirus Sales Share by Manufacturers in 2024
Figure 22. Global Oncolytic Adenovirus Revenue Share by Manufacturers in 2024
Figure 23. Global 5 and 10 Largest Oncolytic Adenovirus Players: Market Share by Revenue in Oncolytic Adenovirus in 2024
Figure 24. Oncolytic Adenovirus Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. Global Oncolytic Adenovirus Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 26. North America Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 27. North America Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 28. United States Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Canada Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Europe Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 31. Europe Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 32. Germany Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Russia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Oncolytic Adenovirus Sales Market Share by Region (2020-2031)
Figure 38. Asia Pacific Oncolytic Adenovirus Revenue Market Share by Region (2020-2031)
Figure 39. China Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Japan Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. South Korea Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. India Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Australia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. China Taiwan Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Latin America Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 47. Latin America Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 48. Mexico Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Brazil Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Argentina Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Colombia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Oncolytic Adenovirus by Type (2020-2031)
Figure 58. Global Revenue Market Share of Oncolytic Adenovirus by Type (2020-2031)
Figure 59. Global Oncolytic Adenovirus Price (US$/Unit) by Type (2020-2031)
Figure 60. Global Sales Market Share of Oncolytic Adenovirus by Application (2020-2031)
Figure 61. Global Revenue Market Share of Oncolytic Adenovirus by Application (2020-2031)
Figure 62. Global Oncolytic Adenovirus Price (US$/Unit) by Application (2020-2031)
Figure 63. Oncolytic Adenovirus Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Oncolytic Adenovirus Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Oncolytic Adenovirus Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Oncolytic Adenovirus Market Competitive Situation by Manufacturers in 2024
Table 4. Global Oncolytic Adenovirus Sales (Units) of Key Manufacturers (2020-2025)
Table 5. Global Oncolytic Adenovirus Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Oncolytic Adenovirus Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Oncolytic Adenovirus Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Oncolytic Adenovirus Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Oncolytic Adenovirus, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oncolytic Adenovirus, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oncolytic Adenovirus, Product Type & Application
Table 12. Global Key Manufacturers of Oncolytic Adenovirus, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oncolytic Adenovirus by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Adenovirus as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oncolytic Adenovirus Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Oncolytic Adenovirus Sales by Region (2020-2025) & (Units)
Table 18. Global Oncolytic Adenovirus Sales Market Share by Region (2020-2025)
Table 19. Global Oncolytic Adenovirus Sales by Region (2026-2031) & (Units)
Table 20. Global Oncolytic Adenovirus Sales Market Share by Region (2026-2031)
Table 21. Global Oncolytic Adenovirus Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Oncolytic Adenovirus Revenue Market Share by Region (2020-2025)
Table 23. Global Oncolytic Adenovirus Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Oncolytic Adenovirus Revenue Market Share by Region (2026-2031)
Table 25. North America Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 27. North America Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 28. North America Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 32. Europe Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 33. Europe Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Oncolytic Adenovirus Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Oncolytic Adenovirus Sales by Region (2020-2025) & (Units)
Table 37. Asia Pacific Oncolytic Adenovirus Sales by Region (2026-2031) & (Units)
Table 38. Asia Pacific Oncolytic Adenovirus Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Oncolytic Adenovirus Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 42. Latin America Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 43. Latin America Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Oncolytic Adenovirus Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Oncolytic Adenovirus Sales by Country (2020-2025) & (Units)
Table 47. Middle East and Africa Oncolytic Adenovirus Sales by Country (2026-2031) & (Units)
Table 48. Middle East and Africa Oncolytic Adenovirus Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Oncolytic Adenovirus Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Oncolytic Adenovirus Sales (Units) by Type (2020-2025)
Table 51. Global Oncolytic Adenovirus Sales (Units) by Type (2026-2031)
Table 52. Global Oncolytic Adenovirus Sales Market Share by Type (2020-2025)
Table 53. Global Oncolytic Adenovirus Sales Market Share by Type (2026-2031)
Table 54. Global Oncolytic Adenovirus Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Oncolytic Adenovirus Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Oncolytic Adenovirus Revenue Market Share by Type (2020-2025)
Table 57. Global Oncolytic Adenovirus Revenue Market Share by Type (2026-2031)
Table 58. Global Oncolytic Adenovirus Price (US$/Unit) by Type (2020-2025)
Table 59. Global Oncolytic Adenovirus Price (US$/Unit) by Type (2026-2031)
Table 60. Global Oncolytic Adenovirus Sales (Units) by Application (2020-2025)
Table 61. Global Oncolytic Adenovirus Sales (Units) by Application (2026-2031)
Table 62. Global Oncolytic Adenovirus Sales Market Share by Application (2020-2025)
Table 63. Global Oncolytic Adenovirus Sales Market Share by Application (2026-2031)
Table 64. Global Oncolytic Adenovirus Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Oncolytic Adenovirus Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Oncolytic Adenovirus Revenue Market Share by Application (2020-2025)
Table 67. Global Oncolytic Adenovirus Revenue Market Share by Application (2026-2031)
Table 68. Global Oncolytic Adenovirus Price (US$/Unit) by Application (2020-2025)
Table 69. Global Oncolytic Adenovirus Price (US$/Unit) by Application (2026-2031)
Table 70. Merck Company Information
Table 71. Merck Description and Business Overview
Table 72. Merck Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Merck Oncolytic Adenovirus Product
Table 74. Merck Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Roche Oncolytic Adenovirus Product
Table 79. Roche Recent Developments/Updates
Table 80. Transgene Company Information
Table 81. Transgene Description and Business Overview
Table 82. Transgene Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Transgene Oncolytic Adenovirus Product
Table 84. Transgene Recent Developments/Updates
Table 85. Agenus Company Information
Table 86. Agenus Description and Business Overview
Table 87. Agenus Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Agenus Oncolytic Adenovirus Product
Table 89. Agenus Recent Developments/Updates
Table 90. Oncorus Company Information
Table 91. Oncorus Description and Business Overview
Table 92. Oncorus Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Oncorus Oncolytic Adenovirus Product
Table 94. Oncorus Recent Developments/Updates
Table 95. Viralytics Company Information
Table 96. Viralytics Description and Business Overview
Table 97. Viralytics Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Viralytics Oncolytic Adenovirus Product
Table 99. Viralytics Recent Developments/Updates
Table 100. Amgen Company Information
Table 101. Amgen Description and Business Overview
Table 102. Amgen Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Amgen Oncolytic Adenovirus Product
Table 104. Amgen Recent Developments/Updates
Table 105. Targovax Company Information
Table 106. Targovax Description and Business Overview
Table 107. Targovax Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Targovax Oncolytic Adenovirus Product
Table 109. Targovax Recent Developments/Updates
Table 110. Sorrento Therapeutics Company Information
Table 111. Sorrento Therapeutics Description and Business Overview
Table 112. Sorrento Therapeutics Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sorrento Therapeutics Oncolytic Adenovirus Product
Table 114. Sorrento Therapeutics Recent Developments/Updates
Table 115. Shanghai Pharma Sunway Biotech Company Information
Table 116. Shanghai Pharma Sunway Biotech Description and Business Overview
Table 117. Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Shanghai Pharma Sunway Biotech Oncolytic Adenovirus Product
Table 119. Shanghai Pharma Sunway Biotech Recent Developments/Updates
Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 122. Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Jiangsu Hengrui Pharmaceuticals Oncolytic Adenovirus Product
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 125. Fosun Pharma Company Information
Table 126. Fosun Pharma Description and Business Overview
Table 127. Fosun Pharma Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Fosun Pharma Oncolytic Adenovirus Product
Table 129. Fosun Pharma Recent Developments/Updates
Table 130. BeiGene Company Information
Table 131. BeiGene Description and Business Overview
Table 132. BeiGene Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. BeiGene Oncolytic Adenovirus Product
Table 134. BeiGene Recent Developments/Updates
Table 135. Junshi Biosciences Company Information
Table 136. Junshi Biosciences Description and Business Overview
Table 137. Junshi Biosciences Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Junshi Biosciences Oncolytic Adenovirus Product
Table 139. Junshi Biosciences Recent Developments/Updates
Table 140. Chengdu Kanghua Biological Products Company Information
Table 141. Chengdu Kanghua Biological Products Description and Business Overview
Table 142. Chengdu Kanghua Biological Products Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Chengdu Kanghua Biological Products Oncolytic Adenovirus Product
Table 144. Chengdu Kanghua Biological Products Recent Developments/Updates
Table 145. 3SBio Company Information
Table 146. 3SBio Description and Business Overview
Table 147. 3SBio Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. 3SBio Oncolytic Adenovirus Product
Table 149. 3SBio Recent Developments/Updates
Table 150. Changchun High & New Technology Industries Company Information
Table 151. Changchun High & New Technology Industries Description and Business Overview
Table 152. Changchun High & New Technology Industries Oncolytic Adenovirus Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Changchun High & New Technology Industries Oncolytic Adenovirus Product
Table 154. Changchun High & New Technology Industries Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Oncolytic Adenovirus Distributors List
Table 158. Oncolytic Adenovirus Customers List
Table 159. Oncolytic Adenovirus Market Trends
Table 160. Oncolytic Adenovirus Market Drivers
Table 161. Oncolytic Adenovirus Market Challenges
Table 162. Oncolytic Adenovirus Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oncolytic Adenovirus
Figure 2. Global Oncolytic Adenovirus Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oncolytic Adenovirus Market Share by Type: 2024 & 2031
Figure 4. Conditional Replication Adenovirus Product Picture
Figure 5. Armed Oncolytic Adenovirus Product Picture
Figure 6. Global Oncolytic Adenovirus Market Value by Application (2020-2031) & (US$ Million)
Figure 7. Global Oncolytic Adenovirus Market Share by Application: 2024 & 2031
Figure 8. Head And Neck Cancer
Figure 9. Liver Cancer
Figure 10. Colorectal Cancer
Figure 11. Prostate Cancer
Figure 12. Ovarian Cancer
Figure 13. Non-Small Cell Lung Cancer
Figure 14. Glioblastoma
Figure 15. Others
Figure 16. Global Oncolytic Adenovirus Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Oncolytic Adenovirus Market Size (2020-2031) & (US$ Million)
Figure 18. Global Oncolytic Adenovirus Sales (2020-2031) & (Units)
Figure 19. Global Oncolytic Adenovirus Average Price (US$/Unit) & (2020-2031)
Figure 20. Oncolytic Adenovirus Report Years Considered
Figure 21. Oncolytic Adenovirus Sales Share by Manufacturers in 2024
Figure 22. Global Oncolytic Adenovirus Revenue Share by Manufacturers in 2024
Figure 23. Global 5 and 10 Largest Oncolytic Adenovirus Players: Market Share by Revenue in Oncolytic Adenovirus in 2024
Figure 24. Oncolytic Adenovirus Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. Global Oncolytic Adenovirus Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 26. North America Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 27. North America Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 28. United States Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Canada Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Europe Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 31. Europe Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 32. Germany Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. France Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. U.K. Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Italy Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Russia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Asia Pacific Oncolytic Adenovirus Sales Market Share by Region (2020-2031)
Figure 38. Asia Pacific Oncolytic Adenovirus Revenue Market Share by Region (2020-2031)
Figure 39. China Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Japan Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. South Korea Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. India Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Australia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. China Taiwan Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Latin America Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 47. Latin America Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 48. Mexico Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Brazil Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Argentina Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Colombia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Oncolytic Adenovirus Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Oncolytic Adenovirus Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. UAE Oncolytic Adenovirus Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Oncolytic Adenovirus by Type (2020-2031)
Figure 58. Global Revenue Market Share of Oncolytic Adenovirus by Type (2020-2031)
Figure 59. Global Oncolytic Adenovirus Price (US$/Unit) by Type (2020-2031)
Figure 60. Global Sales Market Share of Oncolytic Adenovirus by Application (2020-2031)
Figure 61. Global Revenue Market Share of Oncolytic Adenovirus by Application (2020-2031)
Figure 62. Global Oncolytic Adenovirus Price (US$/Unit) by Application (2020-2031)
Figure 63. Oncolytic Adenovirus Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Coke Oven Inspection Intelligent Robot Market Research Report 2025
Apr 16, 25
Global Explosion-Proof Fire Extinguishing Reconnaissance Robot Market Research Report 2025
Apr 16, 25
Global Electric Wheeled Inspection Robot Market Research Report 2025
Apr 16, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232